profit from every $100 of sales.
$0$100
IGC Pharma
$0.20+1.48% today
-48.6% in 1 year
1-year low $0.191-year high $0.39
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What IGC Pharma sold, what it kept, and what it did with the cash.
Sales went from $397,000 in 2022 to $1.27 million in 2025, with -$7.12 million of profit last year.
SalesProfit
IGC Pharma vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| IGC Pharma | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads IGC Pharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 1 | 1 | 1 | |
| 0 | 0 | 1 | 1 | |
| -15 | -12 | -10 | -7 | |
| -15 | -11 | -9 | -7 | |
| -15 | -12 | -13 | -7 | |
| -0.30 | -0.22 | -0.22 | -0.09 | |
| 48.9% | 48.5% | 54.5% | 48.7% | |
| -3,886.1% | -1,270.1% | -728.5% | -585.8% | |
| -3,782.4% | -1,263.0% | -966.5% | -560.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 27 | 17 | 10 | 9 |
| Cash | 10 | 3 | 1 | 0 |
| Total debt | 1 | 0 | 0 | 0 |
| Total liabilities | 3 | 2 | 3 | 2 |
| 24 | 15 | 7 | 6 | |
| 50 | 53 | 59 | 77 | |
| -49.7% | -59.4% | -101.0% | -89.6% | |
| -62.8% | -77.2% | -177.6% | -112.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -7 | -7 | -5 | -4 | |
| 1 | 1 | 1 | 0 | |
| -8 | -8 | -6 | -4 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 2 | 3 | 2 | 1 |
Valuation
- –
- –
- –
- 4.0×
- 18.3×
- –
- –
- -18.9%
- -30.7%
- 0.0%
Profitability
- 48.7%
- -585.8%
- -560.3%
- -633.9%
- -121.0%
- -88.0%
- -76.5%
- -55.0%
- -121.2%
- 410.2%
Growth
- +47.4%
- –
- +7.6%
- –
- +16.2%
Financial health
- -0.0×
- 0.02
- 1.5%
- –
- 0.83
- 0.53
- 0.12
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 12%of 889
Bottom 4%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 3, 2026 | -0.01 | -0.02 | +50.0% |
| Nov 14, 2025 | -0.02 | -0.02 | +0.0% |
| Aug 14, 2025 | -0.02 | -0.03 | +33.3% |
| Jun 27, 2025 | -0.01 | -0.02 | +50.0% |
| Feb 14, 2025 | -0.02 | -0.03 | +33.3% |
| Nov 12, 2024 | -0.02 | -0.02 | −23.1% |
| Aug 8, 2024 | -0.03 | -0.03 | −15.9% |
| Jun 24, 2024 | -0.04 | -0.00 | −900.0% |
News
The Healthcare ETF Showdown: Broad Global Health or Targeted Pharma Power?Yahoo Finance · Nov 7, 2026Nuvectis Pharma, Inc. Q3 2026 Earnings Call SummaryYahoo Finance · Nov 4, 2026Royalty Pharma plc Q3 2026 Earnings Call SummaryYahoo Finance · Nov 4, 20263 Reasons Royalty Pharma Is a Dividend Stock You Never Have to SellYahoo Finance · Oct 22, 2026Stock Market Today: Dow Rises As Oil Prices Back Off; Biotech, Pharma Stocks Shine (Live Coverage)Yahoo Finance · Oct 20, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
27No pass
Benjamin Graham
23No pass
Philip Fisher
49No pass
Peter Lynch
100Pass
Joel Greenblatt
0No pass
Charlie Munger
39No pass
Terry Smith
37No pass
Questions about IGC Pharma
Is IGC Pharma a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the IGC Pharma AI analysis
What does IGC Pharma do?
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It is in Biotechnology.
Does IGC Pharma pay a dividend?
No. IGC Pharma does not pay a dividend at the moment.
Is IGC Pharma stock halal?
Yes. IGC Pharma passes our halal screen: its business is permitted and its debt is 1% of its market value, under the 30% limit. How we check
How has IGC Pharma stock done over the past year?
Down 48.6% over the past twelve months, to $0.20. It traded between $0.19 and $0.39 and is 48.6% below its high.
Who are IGC Pharma's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with IGC Pharma's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.